Dimerix and Takeda Cambridge Limited Sign Agreement to Use GPCR-HIT Platform in Discovery Program

PERTH, Australia--(BUSINESS WIRE)-- Dimerix Bioscience Pty Ltd, a pre-clinical stage product company developing a pipeline of ’best in class’ lead products with highly specific activity and with reduced risk of off-target effects, today announced that it has entered into a research agreement with Takeda Cambridge Limited, a UK based subsidiary of Takeda Pharmaceutical Company Limited, Japan’s largest pharmaceutical company.

Under the agreement, Dimerix will use its GPCR-HIT platform and leading insights into the ability of G-Protein Coupled Receptors (GPCRs) to form complexes, called heteromers, to work with undisclosed GPCRs of interest to Takeda.

“Dimerix’ GPCR-HIT platform enables the development of more specific drugs that take into account the signaling profile of GPCRs acting in heteromeric complexes,” said Tim Grogan, CEO of Dimerix. “We are very pleased to be working with Takeda to apply our GPCR-HIT technology. Our interactions with Takeda have been very impressive.”

“We are pleased to enter into this agreement to apply Dimerix’ GPCR-HIT platform,” said Mark Carlton, President of Takeda Cambridge Limited. “This work will continue to build on our knowledge of key GPCRs, which are drug targets of major significance.”

About GPCRs and Dimerix’ GPCR-HIT Platform:

Dimerix’ proprietary G-Protein Coupled Receptor Heteromer Identification Technology (GPCR-HIT) platform is used to identify complexes formed by GPCRs known as GPCR heteromers. The platform is also used to screen for and to profile compounds that interact with GPCR heteromers specifically or allosterically. Use of GPCR-HIT significantly expands the scope of GPCR-based drug discovery and development through the identification of compounds having biased intracellular signaling that is mediated through the GPCR heteromers. The technology can be applied at various stages of drug development including screening for leads and profiling of compounds, including profiling for potential toxicity or other side effects of compounds that are believed to act through monomeric GPCRs. For further details see: Pfleger KD: New Technology to Identify Potential Novel G-Protein Coupled Receptor Heterodimers and Heterodimer-specific Compounds. J Biomol Screen 2009, 14:890.

About Dimerix Bioscience Pty Ltd:

Dimerix is a Perth-based drug discovery company focused on developing pharmaceutical products targeting heteromers or complexes of GPCRs. Approximately 40% of all currently marketed pharmaceutical products worldwide target GPCRs. Dimerix’ GPCR-HIT platform, originally acquired from The University of Western Australia, is based on extensive research from the laboratories of scientists Professor Karin Eidne and Associate Professor Kevin Pfleger at the Laboratory for Molecular Endocrinology at the Western Australian Institute for Medical Research. The company’s drug discovery and development portfolio is currently focused on programs for oncology, metabolic, cardiovascular and inflammatory disease indications. Dimerix is privately held. Additional information about Dimerix is available through its corporate website, www.dimerix.com.

About Takeda Cambridge Limited:

Located in Cambridge, UK, Takeda Cambridge Limited has established world-class target identification, validation and drug discovery capabilities. The company has developed a promising pipeline of novel drug discovery targets and compounds in key areas of unmet medical need.

About Takeda Pharmaceutical Company Limited:

Located in Osaka, Japan, Takeda is a research-based global company with its main focus on pharmaceuticals. As the largest pharmaceutical company in Japan and one of the global leaders of the industry, Takeda is committed to striving toward better health for individuals and progress in medicine. Additional information about Takeda is available through its corporate website, www.takeda.com.



CONTACT:

Dimerix Bioscience Pty Ltd
Tim Grogan, Chief Executive Officer, +61 (0) 438 655 452
[email protected]
www.dimerix.com

KEYWORDS:   Australia  United Kingdom  Europe  Asia Pacific  Australia/Oceania  Japan

INDUSTRY KEYWORDS:   Health  Biotechnology  Oncology  Pharmaceutical  Research  Science

MEDIA:

Logo
 Logo

Suggested Articles

Half of patients in an early trial of Allogene's off-the-shelf CAR-T cells for lymphoma who received a higher dose of its antibody ALLO-647 responded.

Takeda is tossing out a Shire pipeline med after it couldn't find a buyer.

Ipsen's new hire arrives at a company reeling from a torrent six months that have crushed hopes for its $1 billion bet on a rare disease drug.